LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akcijų sąrašas・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Uždarymo kaina

15.94 -2.51

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.81

Max

16.06

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-23M -14M
Pardavimai	-22M 72M
Pelnas, tenkantis vienai akcijai	-0.09
Pelno marža	-18.944
Darbuotojai	619
EBITDA	-23M -6.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+26.73% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-441M 2.4B
Ankstesnė atidarymo kaina	18.45
Ankstesnė uždarymo kaina	15.94

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

8.81 / 10.18 Palaikymas ir pasipriešinimas

Adaptive Biotechnologies Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-27 23:53; UTC

Karštos akcijos

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

2026-02-27 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

2026-02-27 17:55; UTC

Karštos akcijos

Toronto Stocks Decline, But Remain On Track for Weekly Gains

2026-02-27 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

2026-02-27 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

2026-02-27 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-27 21:30; UTC

Uždarbis

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

2026-02-27 21:30; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

2026-02-27 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

2026-02-27 21:17; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026-02-27 21:10; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

2026-02-27 21:09; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

2026-02-27 21:00; UTC

Uždarbis

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

2026-02-27 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

2026-02-27 20:24; UTC

Rinkos pokalbiai

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

2026-02-27 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

2026-02-27 20:12; UTC

Rinkos pokalbiai

Nike Seen With Further Challenges in China -- Market Talk

2026-02-27 19:44; UTC

Rinkos pokalbiai

Gold Caps Historic Month -- Market Talk

2026-02-27 19:39; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026-02-27 19:38; UTC

Uždarbis

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

2026-02-27 18:53; UTC

Įsigijimai, susijungimai, perėmimai

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

2026-02-27 18:45; UTC

Uždarbis

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

2026-02-27 18:45; UTC

Rinkos pokalbiai

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

2026-02-27 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-27 17:07; UTC

Uždarbis

Pemex Cuts 4Q Loss As Operating Results Improve

2026-02-27 17:00; UTC

Rinkos pokalbiai

Corn Rides Oil Momentum Higher -- Market Talk

2026-02-27 16:31; UTC

Rinkos pokalbiai

Canadian Economy Shows Resilience -- Market Talk

2026-02-27 16:17; UTC

Rinkos pokalbiai

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

2026-02-27 15:49; UTC

Uždarbis

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Adaptive Biotechnologies Corp Prognozė

Kainos tikslas

By TipRanks

26.73% į viršų

12 mėnesių prognozė

Vidutinis 20.86 USD 26.73%

Aukščiausias 22 USD

Žemiausias 20 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Adaptive Biotechnologies Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Adaptive Biotechnologies Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.81 / 10.18Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.